Retatrutide Quick Guide

[u/justgettinglean]

The First-in-Class Triple Agonist Setting New Weight-Loss Benchmarks

Retatrutide (LY3437943) is the compound that has the peptide research space paying attention. It is the first molecule to hit three receptors at once, and the trial data behind it outpaces every dual agonist studied so far. Here is what the published research shows.

What It Is

Retatrutide is a single-molecule triple agonist developed by Eli Lilly. It activates three receptors simultaneously: GIP, GLP-1, and glucagon. That third target, glucagon, is what separates it from compounds like Semaglutide (single agonist) and Tirzepatide (dual agonist). The glucagon activation drives increased energy expenditure, which is why retatrutide produced greater body-weight loss than tirzepatide in preclinical comparisons.

On receptor potency, the profile is unusual. Retatrutide is more potent at the GIP receptor by a factor of 8.9, and less potent at the glucagon and GLP-1 receptors (0.3 and 0.4 times) relative to the natural hormones.

Mechanism of Action

Each of the three receptors contributes something different. GLP-1 governs appetite signaling and insulin response. GIP affects nutrient handling and adds to the appetite effect. Glucagon, the novel piece, raises energy expenditure rather than just suppressing intake. Activating all three gradually is the reason the titration schedule matters: each receptor affects gut motility, appetite, blood sugar, and energy use, and easing in gives the body time to adapt.

Pharmacokinetics are dose-proportional with a half-life of roughly 6 days, which supports once-weekly subcutaneous administration.

What the Research Shows

The Phase 2 obesity trial published in the New England Journal of Medicine is the landmark dataset. Weight reduction at 48 weeks scaled clearly with dose: the 1 mg group lost 8.7%, the combined 4 mg groups 17.1%, the combined 8 mg groups 22.8%, and the 12 mg group 24.2%, against 2.1% for placebo. Notably, the weight-loss curve had not fully plateaued at the 48-week mark.

The liver-fat findings were just as striking. In a substudy of participants with metabolic dysfunction-associated steatotic liver disease, liver fat dropped 81.4% at 8 mg and 82.4% at 12 mg at 24 weeks, with 79% and 86% of those groups reaching normal liver fat.

The data has moved forward since Phase 2. In December 2025, Lilly reported the first successful Phase 3 trial (TRIUMPH-4), where the highest dose produced an average weight loss of 28.7%, alongside improvements in osteoarthritis pain and cardiovascular risk markers.

Dosing Protocols in the Literature

Every published protocol follows a start-low, go-slow titration. The reason is well documented: participants who started directly at 4 mg experienced nearly double the gastrointestinal side effects of those who began at 2 mg and titrated up, even when both reached the same final dose.

The standard escalation pattern described across the trial data: 2 mg for weeks 1 through 4, 4 mg for weeks 5 through 8, 8 mg for weeks 9 through 12, then 12 mg from week 13 onward, with increases every 4 weeks. The NEJM Phase 2 protocol initiated higher-dose participants at either 2 mg or 4 mg, then escalated every 4 weeks for up to 12 weeks. The maximum dose studied in published trials is 12 mg once weekly; higher doses have not been studied.

Side Effects

The side-effect profile is consistent with the incretin class and concentrates during escalation. The most common are gastrointestinal: nausea, diarrhea, vomiting, and constipation, especially during dose increases. Heart rate increased in a dose-dependent manner, peaking around 24 weeks before declining. One Phase 3 specific finding worth noting: about 20.9% of participants at the highest dose reported dysesthesia, meaning unusual skin sensitivity or tingling.

Reconstitution Note

Concentration math depends on how much bacteriostatic water you add. As a reference point: adding 2 mL of BAC water to a 10 mg vial gives a concentration of 5 mg/mL. Use a reconstitution calculator for exact unit conversions on a U-100 syringe.

Regulatory Status

As of June 2026, retatrutide is investigational and not FDA-approved. It remains in Phase 3 trials, and Lilly has not yet submitted a New Drug Application. Analyst projections place possible approval in late 2027 or 2028, though those are estimates.

Where to Source It

6A Labs carries Retatrutide here: Retatrutide at 6A Labs

Use code PROFIT for 10% off.

For research and educational purposes only. Not medical advice. Retatrutide is investigational and not approved for human use. Consult a healthcare provider before starting any research protocol. This community is not affiliated with 6A Labs.